Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Sometimes it is difficult to know what to make of data from even the most reputable institutions. This appears to be the case for a recent study from a Harvard research team.
Filed under: Living with Prostate Cancer | Tagged: cancer, cost, drug coverage, Medicare, non-adherence | Leave a Comment »
In a new paper just published on-line in the Journal of Urology, Kapoor et al. have provided data on trends in the utilization of various major types of treatment for the management of localized prostate cancer among Medicare beneficiaries in the USA between 2006 and 2008.
Filed under: Management, Treatment | Tagged: beneficiary, cryotherapy, Medicare, radiation, surgery, Treatment, utilization | Leave a Comment »
The Centers for Medicare and Medicaid Services (CMS) proposed yesterday that there is sufficient and adequate evidence to conclude that the use of autologous cellular immunotherapy treatment — sipuleucel-T (Provenge®) – improves health outcomes for Medicare beneficiaries
Filed under: Management, Treatment | Tagged: CMS, coverage, Medicare, Provenge, sipuleucel-T | Leave a Comment »
Physicians and researchers on a panel advising the Centers for Medicare & Medicaid Services (CMS) gave Provenge® a favorable vote at a “National Coverage Analysis” hearing yesterday in Washington, DC. You could almost hear the world of prostate cancer survivors, their physicians, Dendreon investors, and other drug development companies breathe a sigh of relief!
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: coverage, Medicare, Provenge, sipuleucel-T | 2 Comments »
Financial disincentives related to prescribing of LHRH agonists introduced in 2003 have clearly been associated with changes in actual physician prescriptions for drugs like Lupron and Zoladex in the immediately following years.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: appropriate use, cost, finance, incentive, LHRH agonist, Medicare | 3 Comments »
Yesterday evening, the Centers for Medicare and Medicaid Services (CMS) announced that it was opening a “national coverage analysis to determine whether or not autologous cellular immunotherapy [for prostate cancer with sipuleucel-T/Provenge] is reasonable and necessary.”
Filed under: Management | Tagged: coverage, Medicaid, Medicare, Provenge, sipuleucel-T | 3 Comments »
Whether we like it or not, there are significant costs associated with the diagnosis and management of prostate cancer over time. And there are very few good data (to date) on the relative costs associated with differing types of treatment over time.
Filed under: Living with Prostate Cancer | Tagged: cost, Medicare | 2 Comments »
Reuters has published a summary report on the discussions of a Medicare advisory panel (MedCAC) held yesterday to address the value of different types of radiation therapy in the treatment of early-stage prostate cancer.
Filed under: Management | Tagged: coverage, CyberKnife, Medicare, radiation | Leave a Comment »
An article in today’s New York Times addresses an issue of potentially growing importance for Medicare beneficiaries with prostate cancer. Is the form of treatment you want covered where you live?
Filed under: Management, Treatment | Tagged: CyberKnife, Medicare | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site